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As part of a development programme for a range of new CFC-free beclomethasone dipropionate (BDP) inhalers, 
two multicentre double-blind studies have been conducted to compare the therapeutic equivalence of a new 
HFA-134a propellant-formulated BDP metered-dose inhaler (Norton Healthcare Ltd, London, U.K.) with a CFC 
counterpart for the management of adult patients with all grades of asthma. Doses of 100 pug qds for 6 weeks were 
administered in a low dose study and in a high dose study 500,ug qds doses were given for 12 weeks. 
Efficacy assessments included lung function (FEV,) in the clinic and asthma symptoms, peak flow rates and 
bronchodilator use by patients on diary cards. Safety parameters measured included routine haematology and 
biochemistry (including serum cortisols), clinical adverse events and throat swabs for Candida spp. 
Both CFC and HFA-formulations of inhaled BDP produced similar and significant improvements in lung 
function and asthma symptoms. In the low dose study, baseline to endpoint FEV, increased from 2.2 * 0.5 1 to 
2.5 & 0.8 1 (P=O.OOOl) with BDP-CFC and from 2.2 * 0.5 1 to 2.6 f 0.8 1 with BDP-HFA (P=O.OOOl), with no 
significant differences between treatments. In the high dose study, corresponding increases were 2.1 * 0.7 1 to 
2.4 f 0.9 1 (P=O.O002) for BDP-CFC and 2.1 f 0.7 1 to 2.3 f 0.7 1 (P=O.O17) for BDP-HFA. PEF also improved 
similarly on both treatments in both studies. Both formulations were well tolerated with no difference in the pattern 
of adverse events, effect on serum cortisol or Candida colonization. 
These studies showed that, in the management of asthma, the new HFA-formulated BDP metered dose inhaler 
is equivalent to, and directly substitutable for, the older CFC-formulated product at the same dose, making 
change-over for patients straightforward. 
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Introduction 
Beclomethasone dipropionate (BDP) is a well-established 
inhaled corticosteroid used for the prophylactic manage- 
ment of asthma. It is usually given via a pressurized 
metered dose inhaler (MDI). Currently most MDIs utilize a 
conventional chlorofluorocarbon (CFC) propellant to form 
the aerosol for inhalation. However, under the terms of the 
Montreal Protocol (l), use of CFCs is being phased out 
world-wide, including those used in medical devices, since 
these substances are implicated in damage to the earth’s 
ozone layer. Recently, non-CFC propellants have been 
deployed which lack ozone-depleting potential. One of 
those to be used as a replacement propellant in medical 
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inhalers is l,l, 1,2-tetrafluoroethane, otherwise known as 
HFA-134a. Extensive toxicological testing of HFA-134a 
has taken place under the auspices of the International 
Pharmaceutical Aerosol Consortium for Toxicology Test- 
ing (IPACT-1). Further clinical testing by pharmaceutical 
companies has shown this propellant to be free of any 
serious toxicity. In healthy man both single and multiple 
doses of HFA-134a are very well tolerated at dose levels 
above those likely to be used in therapeutic practice from 
inhalers (2-4). Furthermore, two salbutamol inhalers and 
two BDP inhalers containing HFA-134a are already 
licensed for the treatment of asthma in some countries 
(5,7-12). Although a 1:l dose switch represents the most 
convenient and least confusing strategy for patients and 
doctors moving to the new CFC-free inhalers, a number of 
studies with one of the new BDP-HFA formulations have 
claimed efficacy at half the dose of the former CFC 
equivalent (7-9). 
The present clinical studies in the treatment of moderate 
to severe asthma were planned to assess the therapeutic 
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comparability of an alternative new formulation of 
BDP-HFA 134a in a MD1 (Norton Healthcare Ltd, 
London, U.K.) with a conventional BDP-CFC MD1 
(Becotide@ or Becloforte@, Allen & Hanbury’s Ltd, U.K.). 
Prior in-house studies in healthy subjects with this new 
HFA formulation had shown that both single and multiple 
doses in the range of 50-25Opg were equally as well 
tolerated as those from the established BDP-CFC 
formulation. 
Material and Methods 
The research protocols comprised two multicentre studies: 
one to evaluate low dose BDP (50 ,ug shot - ‘) and another 
to evaluate high-dose BDP (250 pg shot - ‘) in both HFA 
and CFC formulations in standard MDIs. The clinical 
studies were conducted according to the principles of Good 
Clinical Research Practice in Europe (1991) and the 
Declaration of Helsinki (Hong Kong revision), as well as 
conforming to the guidelines set out by the Committee for 
Proprietary Medicinal Products on replacement of CFCs in 
metered dose inhalers (14). Both studies were approved by 
the local ethics committees of the centres concerned and by 
the respective national regulatory authorities. 
STUDY SUBJECTS 
Adult asthmatic patients (>12 years) of either sex, from 
general practice or hospital centres in the U.K., Eire and 
Poland, were eligible for the studies. 
To satisfy inclusion criteria in both studies, patients 
needed to demonstrate a forced expiratory volume in 1 s 
(FEV,) of 5&80% of predicted normal for their age, height 
and gender and a reversibility of 10% or more in FEV, 
following 200 pug of inhaled salbutamol. 
All patients gave written, informed consent to participate 
in the studies. 
Low dose study 
Patients enrolled into the low dose study were currently 
receiving only inhaled bronchodilator therapy on an 
‘as required’ basis, or inhaled sodium cromoglycate or 
nedocromil sodium. Those on oral corticosteroids, or who 
had been prescribed such agents in the previous 3 months, 
or who had taken more than three short courses of oral 
corticosteroids in the past year were excluded. Other 
exclusion criteria included concurrent systemic illness or 
recent hospital admission for asthma exacerbation, therapy 
for an upper respiratory tract infection, patients who were 
pregnant or nursing, and those with significantly abnormal 
laboratory screens. In addition, known or suspected hyper- 
sensitivity to the study medications, or those patients 
unlikely to be compliant with the study procedures also 
constituted grounds for exclusion. 
High dose study 
At baseline, patients in the high dose study were currently 
taking inhaled BDP-CFC at doses of 80&2000 pg daily via 
(a) ( BDP-CFC ;OO pg qds , 
BDP-HFA 100 pg qds 
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FIG. 1. Study schematics. (a) Low-dose study; (b) high- 
dose study. 
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an MDI, otherwise inclusion and exclusion criteria were the 
same as for the low dose study. 
STUDY DESIGN 
Both studies were multicentre, double-blind and of 
randomized, parallel group design. The study schematics 
are shown in Fig. 1. 
Low dose study 
The low dose study compared BDP-HFA and BDP-CFC in 
doses of lOOpug four times daily (qds) for 6 weeks. Patients 
were seen in the clinic for assessment at the following times: 
at baseline, after 1 day of study treatment and after 3 and 6 
weeks of treatment. 
High dose study 
Following a 2-week baseline period during which patients 
continued their usual asthma medication, the high dose 
study compared BDP-CFC and BDP-HFA in doses of 
5OOpg qds for 12 weeks. Patients were seen in the clinic at 
the start and end of the baseline period and after 3,6,9 and 
12 weeks of study treatment. 
The main variables assessed in both studies included 
lung function, asthma symptoms, vital signs, use of relief 
medication, adverse events, routine haematological and 
biochemical parameters (including 0900 h serum cortisols) 
and oropharyngeal examination plus throat swabs. Com- 
pliance was verified by reference to data on patient diary 
cards and inhaler technique was checked at each study visit. 
METHODS 
In both studies, following initial screening, eligible patients 
attended a baseline examination at the clinic, prior to which 
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TABLE 1. Assessments of asthma symptoms during the studies 
Daytime symptoms 
Grade 0 
Grade 1 
Grade 2 
Grade 3 
Nocturnal symptoms 
Grade 0 
Grade 1 
Grade 2 
Grade 3 
No symptoms at all; unrestricted usual daily activities 
Symptoms occurred, but with little or no discomfort; unrestricted usual daily 
activities 
Symptoms occurred, were sometimes annoying or affecting usual daily 
activities (e.g. walking, dressing) 
Symptoms severe; very little improvement after use of relief inhaler; not able 
to perform usual daily activities 
Slept well; no asthma symptoms 
Restless night, awakened because of asthma symptoms; may have used relief 
inhaler 
Awakened more than once because of asthma symptoms; used relief inhaler 
Awake all night because of asthma symptoms; used relief inhaler 
they were asked to withhold their usual bronchodilator 
medication for a specified period. Lung function (FEV,) 
was assessed by means of spirometry and asthma symptoms 
(cough, wheeze and bronchoconstriction) were graded 
according to a four-point disability scale (absence, mildly 
troublesome, troublesome, very troublesome). Vital signs 
including sitting blood pressure and heart rate were 
recorded. In addition, an oropharyngeal examination was 
made, with a throat swab for Candida spp. culture. A 
venous blood sample was taken for routine haematological 
and clinical chemistry parameters, including 0900 h serum 
cortisol. 
Study medications were dispensed according to a 
randomization code and the patient instructed in their 
correct use. They were also given and shown how to use a 
mini-Wright peak flow meter to record twice daily peak 
flow measurements at home (best of three measurements on 
each occasion, morning and evening). Nocturnal and day- 
time asthma symptoms were recorded by the patients in 
daily diary cards, according to four point scales as above, as 
well as globally, characterizing the degree of interference 
with daytime activities and sleep (Table 1). The number of 
times that relief bronchodilator medication was used was 
also recorded by the patients. 
At follow-up visits in the clinic, patients were assessed 
before taking their morning dose of study medication, 
having withheld any bronchodilator treatment for specified 
preceding intervals, depending on the particular drug. 
Asthma symptoms and vital signs were recorded as before 
and FEV, measured prior to, and 15 and 60 min after, the 
scheduled dose of study treatment. Patient diary cards were 
checked for completeness and any adverse events that had 
occurred in the intervening period were fully documented 
by the investigator. Blood tests (including 0900 h serum 
cortisol measurement) and oropharyngeal swabs were 
repeated at the final visit and additionally at 6 weeks in 
the high dose study. Throat swabs were also taken at 
intermediate visits if clinically warranted. 
Any patient experiencing an exacerbation of asthma 
requiring systemic steroids or an increase in their inhaled 
steroid dose was to be :withdrawn from the study. Those 
concurrently taking oral theophylline or inhaled anti- 
cholinergic therapy maintained the same dose throughout 
the study. Use of other research medications or intranasal, 
parenteral or depot injections of steroids was not permitted. 
ANALYSIS 
A therapeutically relevant difference between the two treat- 
ments in either study was regarded as a difference in mean 
pre-dose FEV, of >0.2 1. To detect this difference statisti- 
cally, with a power of 90%, using 90% confidence intervals, 
a total of 100 evaluable patients was required in each study. 
To allow for drop-outs, target recruitment was set at 120 
patients. Primary endpoint assessments were taken as 
the last available pre-dose FEV, values (mean of three 
readings) and treatment differences were compared using 
analysis of variance. Changes from baseline to endpoint 
FEV, were also calculated in each treatment group. 
Significance levels were regarded as P<O.O5. 
In addition, the proportions of patients with individual 
asthma symptoms (cough, wheeze and bronchoconstric- 
tion) were compared between treatments for each visit, as 
well as the symptomatic overall interference with daytime 
activities and sleep. Use of relief medication and PEF from 
diary card data were also compared between treatments. 
Adverse events were coded according to COSTART classi- 
fication (6). Laboratory data and vital signs were compared 
at each visit with their baseline values. 
All efficacy comparisons were performed both on an 
intention to treat and per protocol basis. 
Results 
EFFICACY 
Results are expressed in terms of the intent-to-treat popu- 
lations in each case although those for the per protocol 
populations were very similar: 
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TABLE 2. Patient demography (safety populations) 
Low-dose study High-dose study 
BDP-CFC BDP-HFA BDP-CFC BDP-HFA 
(n=60) (n=59) (n=59) (n=60) 
Age mean f SD (years) 37.7 f 18.3 39.7 * 16.6 44.7 f 13.3 43.0 f 14.7 
Range 13-72 13-80 1677 1680 
M/F 34126 33126 29130 25135 
Asthma history (years) mean f SD 9.8 f 8.5 11.4 f 8.9 12.8 f 11.1 11 f 8.4 
FEV, (% pred.) mean f SD 67.6 f 8.5 67.2 rk 8.8 70.1 f 15.5 70.0 f 15.2 
TABLE 3. Lung function results (means & SD) (intent-to-treat populations) 
Low-dose study High-dose study 
BDP-CFC BDP-HFA BDP-CFC BDP-HFA 
(n=57) (n=56) (n=54) (n=54) 
FEV, (1) 
Baseline 2.2 f 0.5 2.2 f 0.5 2.1 zk 0.7 2.1 f 0.7 
2.3 f 0.7** Endpoint 
Between treatment 
difference (HFA-CFC) 
90% CI for difference 
Morning PEF (1 min - ‘) 
2.4 * 0.9** 
-0.1 
n.s. 
- 0.34, 0.5 
Baseline 
Endpoint* 
Between treatment 
difference (HFA-CFC) 
90% CI for difference 
2.5 f 0.8** 2.6 zk 0.8** 
0.1 
n.s. 
- 0.14, 0.35 
391.5 f 120.3 374.2 f 113.3 353.6 f 109.4 338.0 f 100.8 
418.7 f 118.5 412.9 f 90.2 375.2 zk 107.7 364.3 f 103.9 
- 5.8 - 10.9 
n.s. n.s. 
- 15.7, 25.6 - 36.1, 19.2 
*, Average for last 3 weeks of treatment; **, P=O.OOOl; n.s., not significant. 
Low dose study 
A total of 119 patients were recruited into the low dose 
study and formed the basis of the safety data population. 
Six patients (three in each group) were excluded from the 
efficacy evaluation for unverifiable data. Thus 113 patients 
comprised the intent-to-treat population, while 97 com- 
pleted all visits as scheduled without protocol violations 
(per protocol population). Baseline patient demography, 
asthma severity and FEV, values were well matched at 
baseline for both groups (Table 2). 
The primary efficacy variable (pre-dose FEV,) showed a 
statistically significant increase in both BDP-CFC and 
BDP-HFA groups (P=O.OOOl) between baseline and end- 
point after 6 weeks of treatment, these being of the order of 
1418%. FEV, increased from 2.2 & 0.5 1 to 2.5 & 0.8 1 with 
BDP-CFC and from 2.2 & 0.5 1 to 2.6 f 0.8 1 with BDP- 
HFA, with no significant differences between treatments 
(Table 3). Although more variable, morning PEF also 
increased similarly with both inhalers, such that the end- 
point difference between treatments was only 5.8 1 min - ’ 
(~2%); results for evening PEF were similar. 
With regard to asthma symptoms, approximately 80% of 
patients reported cough and 90% wheeze at study entry. 
After treatment, both BDP-HFA and BDP-CFC produced 
similar clinically relevant reductions of approximately 50% 
in the numbers of patients with these symptoms (Table 4). 
There was no overall difference in the use of relief medica- 
tion by the two groups in either study, although few 
patients needed to use it. 
High dose study 
The total number of patients enrolled in the high dose study 
was 127, of which 19 were excluded from the efficacy 
analyses. Eight were withdrawn during baseline either for 
failure to satisfy entry criteria or adverse event, while 
another 11 patients had unverifiable data. Thus 108 patients 
formed the intent-to-treat population (92 per protocol 
population). ;. 
In this study both BDP-CFC and BDP-HFA were alsb 
associated with similar significant improvements in pre- 
dose FEV, from baseline to endpoint: from 2.1 f 0.7 1 to 
2.4 f 0.9 1 (P=O*OOO2) for BDP-CFC and from 2.1 + 0.7 1 
TABLE 4. Proportion of patients with cough and wheeze 
(ITT population) 
BDP-CFC BDP-HFA P-value 
Cough 
Low-dose study 
Baseline 46157 (80.7%) 45/56 (80.3%) 0.963 
Endpoint 22148 (458%) 14/47 (29.8%) 0.109 
High-dose study 
Baseline 44/54 (81.5%) 43/54 (79.6%) 0.81 
Endpoint 23/47 (48.9%) 17/47 (36.2%) 0.21 
Wheeze 
Low-dose study 
Baseline 53/57 (92.3%) 50/56 (89.3%) 0.491 
Endpoint 19/48 (39.6%) 17/47 (36.2%) 0.733 
High-dose study 
Baseline 49/54 (90.7%) 48154 (88.9%) 0.75 
Endpoint 22/47 (46.8%) 19/47 (40.4%) 0.53 
to 2.3 +Z 0.7 1 (P=O.O17) for BDP-HFA (Table 3). At the 
end of the study, there were no significant differences 
in either pre- or post-dose FEV, between treatments. 
Although increases in morning and evening PEF based on 
diary card data were also detected, baseline PEF values 
were not well matched between treatment groups. To 
increase precision an analysis of covariance, with correction 
for baseline, was performed. This showed similar responses 
in both parameters between treatments with no significant 
differences at endpoint. 
Treatment-related reductions in the proportions of 
patients presenting with cough, wheeze or bronchoconstric- 
tion in the high dose study paralleled those of the low dose 
study, being similar for both groups (Table 4). 
Thus, both studies showed that the improvements in lung 
function and asthma symptoms were similar for equivalent 
doses of BDP-CFC and BDP-HFA. 
TOLERABILITY/SAFETY 
A similar incidence and pattern of adverse events were 
reported by patients on both treatments in each study. The 
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majority of these were mild or moderate in severity and did 
not result in treatment withdrawal. The most commonly 
reported adverse events are summarized in Table 5 and 
included candidiasis, infection, pharyngitis, cough, nausea 
and dyspepsia; there was no preponderance of any one type 
of adverse event in either group. The majority were not 
considered treatment-related by the reporting investigator. 
Although oral candidiasis comprised 20% of overall adverse 
events in the high-dose study, a quarter of these patients 
had this as a pre-existing condition. In 22 patients with 
throat swabs positive for Candida albicans at study entry, 
these resolved while under treatment, while 27 developed 
positive throat swabs at some stage during the study. 
Three patients in the low-dose study and five patients in 
the high-dose study were withdrawn due to a variety of 
non-serious adverse events. 
Two patients (one in each study) experienced intercurrent 
exacerbations of asthma after 2 and 4 weeks in the study, 
resulting in their hospitalization and withdrawal from the 
study. These patients recovered fully after additional treat- 
ment. In the investigators’ opinions, these were unlikely to 
be related to study treatment; one case was almost certainly 
due to bronchitis. 
There were no clinically significant changes in vital signs 
or routine laboratory data in either study. No changes of 
note were recorded in serum cortisol in the low dose study. 
As to be expected, some patients had low cortisol values at 
some stage during the high dose study but the proportions 
of these were similar between treatments (31% vs. 36% 
patients on BDP-CFC and BDP-HFA, respectively). A 
number of values that were low at 6 weeks had returned to 
within the normal range at the end of 12 weeks of treatment 
in both groups. All patients were asymptomatic and none 
of the values was considered clinically significant by the 
investigators. Plots of those individual serum cortisol values 
in the high dose study exhibiting abnormalities at any stage 
or marked changes are shown in Fig. 2. 
Discussion 
The present two studies have demonstrated that for doses 
of 4OOpg and 2000 ,ug daily, the newly formulated BDP- 
HFA metered dose inhaler is therapeutically equivalent to 
TABLE 5. Incidence of most commonly reported adverse events [evaluable patients, n (%)] 
Low-dose study High-dose study 
BDP-CFC BDP-HFA BDP-CFC BDP-HFA 
(n=60) (n=59) (n=59) (n=60) 
Patients reporting any adverse event 36 (60%) 34 (58%) 51 (86%) 44 (73%) 
Candidiasis 9 (15%) 7 (12%) 35 (59%) 28 (47%) 
Infection 5 (8%) 6 (10%) 12 (20%) 6 (10%) 
Pharyngitis 11 (18%) 6 (10%) 14 (24%) 9 (15%) 
Cough 2 (3%) 3 (5%) . : 10 (1,7%) 3 (5%) 
Nausea 3 (5%) 3 (5%) 3 (5%) 2 (3%) 
Dyspepsia 4 (7%) .’ 1 (2%) - 
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FIG. 2. Patients showing abnormal serum cortisol values during the high-dose study. (a) BDP-CFC; (b) BDP-HFA; 
normal range 165-172 nmol 1 - ‘. 
the currently established BDP-CFC product. No statisti- 
cally or clinically significant differences were detected in 
terms of the patients’ asthma control covering lung 
function, symptoms, relief medication usage or tolerability. 
Both products produced similar improvements in FEV, and 
PEF, with a progressive reduction in asthma symptoms 
throughout treatment. The BDP-HFA formulations were 
assessed in patients with both moderate and severe asthma 
who were characterized at entry as being sub-optimally 
controlled on their present therapy, as evidenced by their 
lung function data. 
The higher incidence of minor adverse events recorded in 
the high dose study, such as candidiasis, pharyngitis and 
cough, may have been the result of not using spacer devices 
in this study. It is likely that these effects would be greatly 
reduced in normal practice by the use of a spacer or mouth 
rinsing after inhaler use, as is currently recommended 
practice. 
Other recently published studies with another BDP 
inhaler formulated with HFA-I34a (3M Pharmaceuticals, 
St Paul, MN, U.S.A.) have purported to show that it is 
possible to reduce the dose by half when switching patients 
from a BDP-CFC inhaler (7-9), on the basis of improved 
lung deposition with this formulation (10). However, clini- 
cal trials using both half-dose and full dose BDP-HFA 
against equivalent full dose BDP-CFC of these formula- 
tions, within the same study, are lacking. On a practical 
level, it is essential that any theoretical benefit of dose 
reduction when switching patients already stabilized on a 
BDP-CFC inhaler to a CFC-free version needs to be 
carefully balanced against the risks of loss of asthma 
control. Interestingly, another study using these same for- 
mulations has, in contrast, clearly shown that BDP-CFC 
and BDP-HFA are clinically and statistically equivalent on 
a 1:l dose basis (1 l), a finding in keeping with the data 
found in the present studies. 
The exact site of lung deposition for various asthma 
aerosols has not been verified. It is possible that much of 
the dose of BDP from a BDP-HFA inhaler may be 
absorbed systematically from the lung alveoli. This could 
in theory result in increased unwanted effects. Although 
the incidences of adverse events appeared similar in 
studies comparing doses of 800 ,ug BDP-HFA with 1500 pug 
BDP-CFC daily (53% and 59%, respectively) (8) it is 
unknown whether such incidences would be similar or not 
with equivalent doses of the two formulations. Further- 
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more, the similar or low incidence of morning serum 
cortisol values below normal range with this BDP-HFA 
formulation compared with its BDP-CFC counterpart in 
some studies may simply be a result of the lower doses of 
BDP-HFA used (8,12). The effects of higher identical daily 
doses (> 1OOO~g) of BDP-HFA and BDP-CFC were not 
ascertained in previously published work, but on the basis 
of the present studies would appear similar. 
These studies presented here have demonstrated that 
patients may be switched directly from their existing CFC- 
formulated BDP aerosol to the new product formulated 
with HFA propellant at the same dose, without loss 
of asthma control or change in tolerability. Such con- 
siderations are important for patients and healthcare pro- 
fessionals in achieving a seamless transition to the new 
CFC-free asthma inhalers and are in keeping with current 
guidelines on asthma management (13). 
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